This is a community-generated profile. If you work at Replimune Group, to claim it.

Replimune Group develops next-generation oncolytic immunotherapies for cancer treatment201-500 Employees
- Recently fundedRaised funding in the past six months
Replimune Group careers
Replimune is a clinical-stage biotechnology company that develops oncolytic immunotherapies designed to trigger a systemic anti-tumor immune response. Using its proprietary RPx platform based on an engineered herpes simplex virus 1 (HSV-1) backbone, the company aims to treat a broad range of solid tumors. Its first FDA-approved therapy, TUDRIQEV, is indicated for patients with advanced melanoma.
Director, Data Analytics and Reporting
Remote only • Woburn, Massachusetts
$201k – $260k1 month ago
Valuation
$0
Funded over
1 round
Latest round